RecruitingNCT06483698

Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery

Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery: A Retrospective Multi-center Study (EarlyLC-RW)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

20,000 participants

Start Date

Mar 1, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are: * What is the best surgical strategy for patients with early-stage lung cancer? * What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting real-world data on patients with early-stage (Stage I) lung cancer who had surgery to understand long-term outcomes and factors that affect survival and recovery. It is a retrospective study, meaning it looks at patients' past medical records. **You may be eligible if...** - You are 18–85 years old - You were diagnosed with Stage I lung cancer - You underwent surgery for your lung cancer without any prior neoadjuvant (pre-surgery) therapy or radiation - Your records, including imaging and clinical data, are complete **You may NOT be eligible if...** - You received chemotherapy, radiation, or other cancer treatments before surgery - Your medical records are incomplete or contain errors Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.